Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy —…
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in…
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
